Lactic Acid Bacteria and Mucosal Immunity
Corinne Grangette-Leprévost obtained her PhD in 1985 at the University of Lille, in France, studying the genetic of Rhizobium symbiotic bacteria. She performed a post-doc between 1986 and 1989 at the Pasteur Institute of Lille (IPL) working on the dual properties of eosinophils, in particular the role of the IgE receptor. In 1990, she obtained a permanent position at IPL and worked on the immune responses in HIV pathogenesis. After 2 years in a R&D team, she participated in the development of new team at the Institut Pasteur de Lille working on lactic acid bacteria (LAB) and mucosal immunity. She started to develop tools to study the vaccine properties of recombinant LAB and then focused her interest on the probiotic properties of these bacteria in the context of inflammatory bowel diseases. She has been a pioneer in studying the mechanism involved in the anti-inflammatory capacities of lactobacilli, highlighting the role of bacterial cell wall components and host signaling pathways. Since 2012, as a Research Director, she manages her own group studying also beneficial properties of commensal bacteria in the field of metabolic diseases and gut microbiota. Since the departure of Bruno Pot (former team leader), she is now at the head of the LABMI team. She is also member of the scientific board of AlimH (Human nutrition) department at INRA.
It is now established that the commensal bacteria that we harbor in our intestine, so named the gut microbiota, play a crucial role in the maturation of the immune system, the maintenance of the intestinal homeostasis and host metabolism, exhibiting thus a beneficial impact in our health and well-being. Alteration of this bacterial ecosystem is observed in numerous chronic pathologies (Inflammatory Bowel Diseases or IBD, diabetes, obesity ...) and thus targeting this microbiota dysbiosis is becoming an important area in human health research. This can be achieved by the use of beneficial bacteria called probiotics. In this context, our team has developed in vitro and in vivo models to select strains with anti-inflammatory or metabolic capacities. We have demonstrated that their effects are strain-specific and identified bacterial factors and signaling pathways involved in their anti-inflammatory properties. We are now selecting strains able to limit obesity and related metabolic imbalances, exploring the mechanisms involved. This work is carried out in close collaboration with industrial partners. We intend to extend this field of application to the commensal bacteria of the human microbiota in order to develop new generation probiotics, better adapted to the digestive tract and able to better express the functions of interest in this environment. An important axis of the team is also to reinforce the natural properties of lactic acid bacteria by genetic manipulation in order to deliver vaccine antigens or therapeutic molecules, directly to mucosal surfaces. We are focusing our use of recombinant lactic acid bacteria to the intestinal and nasal mucosa. Collaboration with F Sebbane’s team allowed us to produce a Yersinia antigen exhibiting not only anti-inflammatory but also vaccination properties. The construction of bioluminescent strains is also a promising issue to better understand their fate in vivo by imaging and their interaction with host cells in the intestine
Group Leader Team "Lactic acid bacteria and Mucosal Immunity" In the context of the microbiota, the team "Lactic acid Bacteria and Mucosal Immunity" focuses their research on the study of the beneficial properties (probiotic) of commensal bacteria against some chronic pathologies and the corresponding mechanisms of action. We also develop recombinant bacteria to reinforce the intrinsic properties of various strains to deliver locally therapeutic molecules.
In order to reinforce our lab team and in the long term to take the leadership of a group, we would like to welcome a senior researcher who can provide additional expertise (microbiota, perinatal colonization) and a strong structuring potential.
Required level: Research Director, Research fellow, Doctorate and HDR (Habilitation à diriger des recherches)
Required expertise: Microbiology, Immunology, Metabolism, Cellular Biology, Animal Experiments (holding habilitation level 1), Molecular Biology.
Application to send to: